Associations

Associations

OrsoBio Presents New Preclinical Data on TLC-6740 and TLC-1180 at the 85th Scientific Sessions of the American Diabetes Association

OrsoBio, a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, announced new preclinical data presenting the efficacy of its mitochondrial protonophores to induce weight loss and provide glycemic benefits while preserving lean mass in diet-induced obese mice. The studies demonstrate the potential of TLC-6740 and TLC-1180, as monotherapy

Associations

Breakthrough Studies Demonstrate Stem Cell-Based Technologies as a Potential Alternative Treatment for Type 1 Diabetes

Stem cell-based technologies have emerged as a promising alternative treatment for type 1 diabetes, offering the potential for insulin independence. Two recent studies presented at the American Diabetes Association's 85th Scientific Sessions in Chicago have revealed advancements in stem cell-derived treatment options, leveraging allogeneic therapies and genetically modified